Literature DB >> 12089530

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Alexander V Panov1, Claire-Anne Gutekunst, Blair R Leavitt, Michael R Hayden, James R Burke, Warren J Strittmatter, J Timothy Greenamyre.   

Abstract

Huntington's disease (HD) is caused by an expansion of exonic CAG triplet repeats in the gene encoding huntingtin protein (Htt), but the mechanisms by which this mutant protein causes neurodegeneration remain unknown. Here we show that lymphoblast mitochondria from patients with HD have a lower membrane potential and depolarize at lower calcium loads than do mitochondria from controls. We found a similar defect in brain mitochondria from transgenic mice expressing full-length mutant huntingtin, and this defect preceded the onset of pathological or behavioral abnormalities by months. By electron microscopy, we identified N-terminal mutant huntingtin on neuronal mitochondrial membranes, and by incubating normal mitochondria with a fusion protein containing an abnormally long polyglutamine repeat, we reproduced the mitochondrial calcium defect seen in human patients and transgenic animals. Thus, mitochondrial calcium abnormalities occur early in HD pathogenesis and may be a direct effect of mutant huntingtin on the organelle.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089530     DOI: 10.1038/nn884

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  325 in total

Review 1.  Mitochondrial bioenergetics and dynamics in Huntington's disease: tripartite synapses and selective striatal degeneration.

Authors:  Jorge M A Oliveira
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 2.  Neuroinflammation in Huntington's disease.

Authors:  Thomas Möller
Journal:  J Neural Transm (Vienna)       Date:  2010-06-10       Impact factor: 3.575

Review 3.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

4.  Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells.

Authors:  Ferdinando Squitieri; Vittorio Maglione; Sara Orobello; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2011-04-26       Impact factor: 3.575

Review 5.  Neuronal degeneration and mitochondrial dysfunction.

Authors:  Eric A Schon; Giovanni Manfredi
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 6.  The mitochondrial permeability transition as a target for neuroprotection.

Authors:  Bruce S Kristal; Irina G Stavrovskaya; Malini V Narayanan; Boris F Krasnikov; Abraham M Brown; M Flint Beal; Robert M Friedlander
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

Review 7.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

8.  Calcium signaling and neurodegenerative diseases.

Authors:  Ilya Bezprozvanny
Journal:  Trends Mol Med       Date:  2009-02-21       Impact factor: 11.951

Review 9.  Neuronal Ca(2+) dyshomeostasis in Huntington disease.

Authors:  Marta Giacomello; Juan C Oliveros; Jose R Naranjo; Ernesto Carafoli
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

Review 10.  Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration.

Authors:  Andrew B Knott; Ella Bossy-Wetzel
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.